Discontinuation Syndrome

Abstract

Discontinuation syndrome is a syndrome, known by clinicians for several decades. The discontinuation syndrome has been observed after abrupt discontinuation of treatment with inhibitors of monoaminoxidase, tricyclic antidepressants and serotonin re-uptake inhibitors. The serotonin re-uptake inhibitor discontinuation syndrome is characterized by signs and symptoms not present previously. Cluster of five somatic symptoms have been described: disequilibrium, gastrointestinal symptoms, flu-like symptoms, sensory disturbances, sleep disturbances. The pharmacologic profile of SSRI plays the key role in the probability of occurrence of discontinuation syndrome. The long half-life of SSRI may prevent the appearance of discontinuation syndrome.